Nifty
Sensex
:
:
11672.30
39160.59
-15.20 (-0.13%)
-55.05 (-0.14%)

Pharmaceuticals & Drugs

Rating :
72/99

BSE: 500420 | NSE: TORNTPHARM

1525.30
-60.40 (-3.81%)
18-Jul-2019 | 10:29AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  1547.00
  •  1547.00
  •  1485.40
  •  1585.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  496351
  •  7570.84
  •  1962.00
  •  1404.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 26,812.81
  • 61.46
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 32,034.87
  • 1.07%
  • 5.68

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 71.25%
  • 2.91%
  • 6.66%
  • FII
  • DII
  • Others
  • 0.16%
  • 10.43%
  • 8.59%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.88
  • 10.52
  • 9.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.77
  • 14.22
  • 7.56

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.56
  • -10.29
  • -22.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.85
  • 22.39
  • 29.04

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.59
  • 6.27
  • 5.60

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.58
  • 14.30
  • 15.57

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
1,856.00
1,722.00
7.78%
2,051.00
1,463.00
40.19%
1,894.00
1,417.00
33.66%
1,872.00
1,362.00
37.44%
Expenses
1,383.00
1,358.00
1.84%
1,490.00
1,104.00
34.96%
1,421.00
1,088.00
30.61%
1,395.00
1,065.00
30.99%
EBITDA
473.00
364.00
29.95%
561.00
359.00
56.27%
473.00
329.00
43.77%
477.00
297.00
60.61%
EBIDTM
25.48%
21.14%
27.35%
24.54%
24.97%
23.22%
25.48%
21.81%
Other Income
17.00
42.00
-59.52%
3.00
74.00
-95.95%
10.00
78.00
-87.18%
27.00
105.00
-74.29%
Interest
123.00
121.00
1.65%
133.00
80.00
66.25%
126.00
51.00
147.06%
122.00
56.00
117.86%
Depreciation
160.00
151.00
5.96%
156.00
94.00
65.96%
152.00
84.00
80.95%
150.00
80.00
87.50%
PBT
-150.00
134.00
-
275.00
259.00
6.18%
205.00
272.00
-24.63%
232.00
266.00
-12.78%
Tax
2.00
-94.00
-
29.00
201.00
-85.57%
26.00
68.00
-61.76%
69.00
78.00
-11.54%
PAT
-152.00
228.00
-
246.00
58.00
324.14%
179.00
204.00
-12.25%
163.00
188.00
-13.30%
PATM
-8.19%
13.24%
11.99%
3.96%
9.45%
14.40%
8.71%
13.80%
EPS
-8.98
13.47
-
14.54
3.43
323.91%
10.58
12.05
-12.20%
9.63
11.11
-13.32%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
-
7,672.80
5,982.26
5,815.69
6,686.93
4,653.45
4,184.72
3,211.14
2,695.92
2,197.79
1,916.04
Net Sales Growth
-
28.26%
2.86%
-13.03%
43.70%
11.20%
30.32%
19.11%
22.67%
14.70%
 
Cost Of Goods Sold
-
2,041.26
1,535.17
1,629.66
1,452.21
1,280.96
1,107.58
807.98
774.38
616.64
516.71
Gross Profit
-
5,631.54
4,447.09
4,186.03
5,234.72
3,372.49
3,077.14
2,403.16
1,921.54
1,581.16
1,399.32
GP Margin
-
73.40%
74.34%
71.98%
78.28%
72.47%
73.53%
74.84%
71.28%
71.94%
73.03%
Total Expenditure
-
5,689.74
4,641.21
4,438.42
3,957.13
3,633.29
3,233.24
2,518.92
2,203.54
1,810.01
1,495.26
Power & Fuel Cost
-
132.46
118.77
107.98
92.59
97.41
71.88
62.80
56.97
42.53
27.40
% Of Sales
-
1.73%
1.99%
1.86%
1.38%
2.09%
1.72%
1.96%
2.11%
1.94%
1.43%
Employee Cost
-
1,403.79
1,135.25
993.41
842.35
841.81
741.10
623.29
531.80
440.44
308.33
% Of Sales
-
18.30%
18.98%
17.08%
12.60%
18.09%
17.71%
19.41%
19.73%
20.04%
16.09%
Manufacturing Exp.
-
511.16
457.58
502.16
353.45
345.98
320.78
278.15
225.27
210.89
223.19
% Of Sales
-
6.66%
7.65%
8.63%
5.29%
7.43%
7.67%
8.66%
8.36%
9.60%
11.65%
General & Admin Exp.
-
811.58
718.38
578.05
637.92
477.59
399.07
324.55
255.89
206.88
177.67
% Of Sales
-
10.58%
12.01%
9.94%
9.54%
10.26%
9.54%
10.11%
9.49%
9.41%
9.27%
Selling & Distn. Exp.
-
738.03
633.06
567.70
547.05
574.40
461.53
393.07
322.29
274.61
225.10
% Of Sales
-
9.62%
10.58%
9.76%
8.18%
12.34%
11.03%
12.24%
11.95%
12.49%
11.75%
Miscellaneous Exp.
-
51.46
43.00
59.46
31.56
15.14
131.30
29.08
36.94
18.03
225.10
% Of Sales
-
0.67%
0.72%
1.02%
0.47%
0.33%
3.14%
0.91%
1.37%
0.82%
0.88%
EBITDA
-
1,983.06
1,341.05
1,377.27
2,729.80
1,020.16
951.48
692.22
492.38
387.78
420.78
EBITDA Margin
-
25.85%
22.42%
23.68%
40.82%
21.92%
22.74%
21.56%
18.26%
17.64%
21.96%
Other Income
-
57.05
307.04
223.30
228.80
285.55
38.13
43.36
52.78
56.23
21.63
Interest
-
503.75
308.48
205.56
183.98
175.16
58.63
33.80
39.45
39.13
29.10
Depreciation
-
617.69
408.60
306.92
237.55
190.74
87.00
82.69
81.73
62.56
66.09
PBT
-
918.67
931.01
1,088.09
2,537.07
939.81
843.98
619.09
423.98
342.33
347.22
Tax
-
125.35
252.87
154.51
610.17
188.84
180.07
146.69
72.32
72.17
116.02
Tax Rate
-
22.32%
27.16%
14.20%
26.04%
20.09%
21.34%
25.22%
20.17%
21.08%
33.41%
PAT
-
436.28
678.11
933.55
1,733.24
750.94
663.88
432.76
284.04
270.17
231.20
PAT before Minority Interest
-
436.31
678.14
933.58
1,733.27
750.97
663.91
434.91
286.30
270.17
231.20
Minority Interest
-
-0.03
-0.03
-0.03
-0.03
-0.03
-0.03
-2.15
-2.26
0.00
0.00
PAT Margin
-
5.69%
11.34%
16.05%
25.92%
16.14%
15.86%
13.48%
10.54%
12.29%
12.07%
PAT Growth
-
-35.66%
-27.36%
-46.14%
130.81%
13.11%
53.41%
52.36%
5.13%
16.86%
 
Unadjusted EPS
-
25.78
40.07
55.17
102.42
44.38
39.23
25.58
33.57
31.93
27.32

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
4,724.35
4,622.19
4,350.13
3,494.10
2,490.56
1,902.43
1,421.93
1,193.83
1,022.40
830.98
Share Capital
84.62
84.62
84.62
84.62
84.62
84.62
42.31
42.31
42.31
42.31
Total Reserves
4,639.73
4,537.57
4,265.51
3,409.48
2,405.94
1,817.81
1,379.62
1,151.52
980.10
788.67
Non-Current Liabilities
3,861.40
4,142.42
2,303.33
1,994.65
2,504.92
926.76
619.81
487.73
397.60
572.29
Secured Loans
3,909.81
4,105.31
2,229.57
1,839.46
2,171.60
730.72
403.19
223.83
170.59
364.64
Unsecured Loans
3.11
6.15
11.26
10.62
13.62
13.74
51.35
98.22
122.45
157.75
Long Term Provisions
288.52
286.66
263.04
246.36
207.49
190.43
129.51
110.45
56.14
0.00
Current Liabilities
5,165.32
5,202.17
2,738.26
3,285.48
2,823.75
2,174.58
1,710.65
1,362.84
1,114.09
549.59
Trade Payables
2,096.74
2,048.24
1,749.32
2,260.22
1,827.72
1,429.13
1,067.74
863.47
615.00
383.60
Other Current Liabilities
1,641.26
1,151.68
687.14
822.28
446.15
371.63
275.83
291.00
312.85
43.39
Short Term Borrowings
934.11
1,625.60
0.00
3.32
319.07
210.43
124.62
138.12
99.57
0.00
Short Term Provisions
493.21
376.65
301.80
199.66
230.81
163.39
242.46
70.25
86.66
122.60
Total Liabilities
13,751.07
13,967.30
9,392.21
8,774.69
7,819.66
5,004.17
3,752.76
3,047.90
2,535.69
1,952.86
Net Block
7,747.71
7,854.68
3,688.44
2,859.08
2,832.66
875.34
819.82
796.87
635.55
541.15
Gross Block
9,935.43
9,449.48
4,909.80
3,793.53
3,542.93
1,420.04
1,278.15
1,199.64
964.28
812.94
Accumulated Depreciation
2,187.72
1,594.80
1,221.36
934.45
710.27
544.70
458.33
402.77
328.73
271.79
Non Current Assets
8,713.53
8,704.89
4,512.74
4,085.66
3,768.25
1,599.69
1,191.87
1,060.78
941.27
670.02
Capital Work in Progress
617.12
646.94
519.49
1,041.58
678.33
534.11
285.28
113.55
179.88
109.82
Non Current Investment
2.09
0.09
0.09
0.09
0.06
0.03
0.03
37.52
20.00
19.05
Long Term Loans & Adv.
150.58
149.44
182.32
99.66
206.92
129.47
62.84
61.37
59.51
0.00
Other Non Current Assets
196.03
53.74
122.40
85.25
50.28
60.74
23.90
46.25
46.34
0.00
Current Assets
5,037.54
5,262.41
4,879.47
4,689.03
4,051.41
3,404.48
2,560.89
1,987.12
1,594.42
1,282.84
Current Investments
351.35
492.27
803.55
779.59
297.59
185.63
60.44
86.52
125.99
122.13
Inventories
1,935.15
1,966.30
1,559.15
1,357.98
1,067.17
1,006.06
923.86
531.56
504.83
323.63
Sundry Debtors
1,435.71
1,253.45
950.89
1,445.09
1,587.26
1,099.42
687.82
522.80
340.40
298.16
Cash & Bank
816.04
867.26
893.72
647.03
567.36
769.42
626.97
674.28
478.80
388.33
Other Current Assets
499.29
586.89
589.54
369.16
532.03
343.95
261.80
171.96
144.41
150.60
Short Term Loans & Adv.
93.46
96.24
82.62
90.18
109.09
84.95
75.95
56.46
49.28
109.06
Net Current Assets
-127.78
60.24
2,141.21
1,403.55
1,227.66
1,229.90
850.24
624.28
480.33
733.26
Total Assets
13,751.07
13,967.30
9,392.21
8,774.69
7,819.66
5,004.17
3,752.76
3,047.90
2,535.69
1,952.86

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,798.08
894.18
1,008.84
2,742.12
810.20
599.42
153.48
499.13
395.01
287.00
PBT
561.66
931.01
1,088.09
2,343.44
939.81
843.98
581.60
358.62
342.33
347.22
Adjustment
1,418.19
606.92
430.27
552.44
337.96
136.79
126.13
79.64
74.80
80.63
Changes in Working Capital
99.39
-360.13
-125.21
423.58
-409.38
-119.68
-421.75
143.58
61.88
-74.82
Cash after chg. in Working capital
2,079.24
1,177.80
1,393.15
3,319.46
868.39
861.09
285.98
581.84
479.01
353.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-281.16
-283.62
-384.31
-577.34
-58.19
-261.67
-132.50
-82.71
-84.00
-66.04
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-241.28
-4,706.95
-786.91
-837.85
-2,162.30
-355.81
-241.70
-136.97
-232.60
-128.71
Net Fixed Assets
-610.74
-4,245.22
-592.01
-471.42
-2,266.57
-308.01
-455.28
-84.67
-52.13
-152.17
Net Investments
138.83
310.79
-17.69
-484.32
-111.97
-131.60
287.55
-47.29
-199.04
13.48
Others
230.63
-772.52
-177.21
117.89
216.24
83.80
-73.97
-5.01
18.57
9.98
Cash from Financing Activity
-1,314.45
3,417.39
-192.91
-1,435.15
1,212.25
86.40
19.73
-192.74
-67.61
-5.25
Net Cash Inflow / Outflow
242.35
-395.38
29.02
469.12
-139.85
330.01
-68.49
169.42
94.80
153.05
Opening Cash & Equivalents
702.04
1,067.57
1,049.86
612.38
955.05
687.41
760.80
604.79
510.45
350.43
Closing Cash & Equivalent
940.06
702.07
1,067.57
1,049.86
864.95
955.05
687.41
760.80
604.79
510.45

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
279.15
273.11
257.04
206.46
147.16
112.41
84.02
70.54
60.42
49.11
ROA
3.15%
5.81%
10.28%
20.89%
11.71%
15.16%
12.79%
10.26%
12.04%
12.81%
ROE
9.34%
15.12%
23.80%
57.92%
34.19%
39.94%
33.25%
25.84%
29.15%
31.20%
ROCE
9.75%
13.81%
20.36%
45.63%
26.98%
35.06%
31.66%
23.65%
25.88%
30.26%
Fixed Asset Turnover
1.50
0.84
1.35
1.82
1.88
3.11
2.60
2.50
2.48
2.54
Receivable days
33.78
67.03
74.66
82.76
105.19
77.81
68.65
58.33
52.95
52.84
Inventory Days
49.01
107.20
90.90
66.19
81.17
84.02
82.53
70.03
68.69
55.03
Payable days
140.28
151.26
171.27
204.35
176.11
158.58
143.69
136.22
103.96
90.60
Cash Conversion Cycle
-57.49
22.96
-5.72
-55.41
10.25
3.25
7.50
-7.86
17.68
17.27
Total Debt/Equity
1.28
1.40
0.58
0.67
1.10
0.59
0.49
0.48
0.56
0.63
Interest Cover
2.11
4.02
6.29
13.74
6.37
15.40
18.21
10.09
9.75
12.93

News Update:


  • USFDA classifies Torrent Pharma’s Dahej facility as OAI
    18th Jul 2019, 09:10 AM

    The company already had submitted its initial response to USFDA and commitments given in response to Form 483 observations have been fulfilled

    Read More
  • Torrent, Glenmark sign licensing agreement for co-marketing of Remogliflozin Etaboriate in India
    11th Jul 2019, 10:36 AM

    Glenmark will manufacture and supply Remogliflozin, while Torrent will market the drug under its own trademark 'Zucator' in India

    Read More
  • Torrent Pharmaceuticals redeems NCDs worth Rs 83 crore
    25th Jun 2019, 12:03 PM

    The company has repaid the same on June 24, 2019

    Read More
  • Torrent Pharmaceuticals reports consolidated net loss of Rs 152 crore in Q4
    21st May 2019, 11:43 AM

    Total consolidated income of the company rose by 7.03% at Rs 1,873.00 crore for quarter ended March 31, 2019

    Read More
  • Torrent Pharmaceuticals raises Rs 100 crore via CPs
    20th May 2019, 09:17 AM

    The tenure of the instrument is 129 days and will mature on September 23, 2019

    Read More
  • Torrent Pharma initiates recalls of over 8 lakh bottles of Losartan Potassium tablets
    13th May 2019, 11:21 AM

    All the ongoing voluntary recalls of the hypertension treatment drug are class II recalls

    Read More
  • Torrent Pharmaceuticals raises Rs 200 crore via CPs
    6th May 2019, 10:25 AM

    ICRA has granted rating of ‘A1 +’ for issuance of Commercial papers by the company

    Read More
  • Torrent Pharmaceuticals gets observations from USFDA for Indrad plant
    26th Apr 2019, 10:38 AM

    The audit at Indrad Plant of the company was carried out by USFDA in the month of April, 2019

    Read More
  • Torrent Pharma’s arm recalls over 10.78 lakh bottles of hypertension tablets from US
    22nd Apr 2019, 12:54 PM

    The reason for the recalls is presence of an impurity in the finished product above the interim acceptable daily intake level of 9.82 per million

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.